Date: 2017-05-12
Type of information: Capital increase
Company: Theradiag (France)
Investors:
Amount: €4,023,994.90
Funding type: capital increase
Planned used:
- The funds raised will enable Theradiag to facilitate and step up its international development, including the launch of BioCLIA® in Europe and the marketing of its auto-immunity, allergy and theranostics ranges.
Others:
- • On May 12, 2017, Theradiag has successfully completed a capital increase by issuing shares to a specific category of persons following an accelerated bookbuilding process. The Company has sold 1,749,563 new shares with par value of €1.70 each, at a price of €2.30 each including the issue premium, for a total amount of €4,023,994.90 and representing 20.21% of the Company’s post-transaction capital. For reference, the interest of a shareholder owning 1% of the Company’s share capital before the issue will be reduced to 0.8% after the issue.
- The issue price represented a discount of 15.6% to the volume-weighted average price in the five trading sessions before the Board’s decision. The capital increase took place through the issue of ordinary shares without preferential subscription rights to a specific category of persons. Settlement of the shares newly issued as part of the capital increase and their admission to Euronext Paris’ Alternext Paris market are expected to take place on May 17, 2017. The new shares will rank for dividends immediately and will be admitted to trading on Alternext Paris under ISIN code FR0004197747 – ALTER. Theradiag’s share capital will be made up of 8,654,944 shares after settlement has taken place.
Post-capital increase and disposal of shares by investment funds managed by Truffle Capital, the ownership structure of the Company’s shares significantly changed. Post-transaction, HOB Capital holds 8.56% of the total capital and the free float is 91.44%. EuroLand Corporate has advised Theradiag.
- • On May 11, 2017, Theradiag announced a capital increase involving the issue of new shares with preferential subscription rights waived for the benefit of a specific category of persons, in accordance with the 15th resolution approved by the Combined General Meeting of Shareholders on April 27, 2017 and with the authorisation of the Board of Directors on May 11, 2017. The Transaction will be for a maximum amount of €4 million. As regards the category of persons for whose benefit preferential subscription rights are being waived, funds will be raised solely from qualified domestic and international investors, with the exception of investors in the USA, Canada, Australia and Japan.
Therapeutic area:
Is general: Yes
